» Go to news main
Lutathera® lutetium (177lu) oxodotreotide for neuroendocrine tumours: a game changer concept in cancer treatment
Posted by Angie Kinsman on
June 30, 2022
in
Nuclear Medicine
Dr. Steven Burrell has published a new article in Le Patient Magazine!
Lutathera® lutetium (177lu) oxodotreotide for neuroendocrine tumours: a game changer concept in cancer treatment
Steven Burrell, MD, FRCPC Head of Nuclear Medicine QEII Health Sciences Centre
"When cancer has spread within the body the 2 main pillars of treatment are drugs such as chemotherapy which are administered internally and distribute throughout the body, and radiation which delivers tumour-destroying radiation from outside the body. However there is another approach..." Read more.
Recent News
- Nova Scotia’s Lung Screening Program expanding to Cape Breton, eastern mainland
- Donor‑supported nuclear medicine technology attracts top medical talent to the QEII
- Building Critical Skills at the Dalhousie Physician Leadership Workshop for Women in Radiology
- CAR/CSTR Practice Guideline on CT Screening for Lung Cancer
- CAR Practice Guideline on Bone Mineral Densitometry Reporting: 2024 Update
- CAR/CSACI Practice Guidance for Contrast Media Hypersensitivity
- ‘A paradigm shift': A first in Canada, donor‑funded nuclear medicine scanner is helping QEII physicians assess and diagnose diseases with precision that wasn’t previously possible — all while tackling waitlists with greater efficiency
- New interventional radiology suite and hybrid operating room at the Halifax Infirmary